Lymphotoxin, NF-κB, and cancer: The dark side of cytokines

Digestive Diseases

Volumn 30, Issue 5, 2012, Pages 453-468

  Bauer, Judith ^a   Namineni, Sukumar ^a   Reisinger, Florian ^a   Zller, Jessica ^a   Yuan, Detian ^a   Heikenwlder, Mathias ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cancer; Cytokine; Lymphotoxin

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOTOXIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENETICS; CELL KILLING; CYTOKINE RELEASE; DISEASE ACTIVITY; GASTROINTESTINAL TRACT; HEPATITIS; HUMAN; IMMUNOLOGY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER INJURY; LIVER REGENERATION; MEDICAL RESEARCH; METASTASIS; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR MICROENVIRONMENT; ADAPTIVE IMMUNITY; ANIMAL; CELL TRANSFORMATION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; INFLAMMATION; LIVER; LIVER DISEASE; LIVER TUMOR; MALE; METABOLISM; MOUSE; REVIEW; VIROLOGY;

ADAPTIVE IMMUNITY; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; FEMALE; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATION; LIVER; LIVER DISEASES; LIVER NEOPLASMS; LYMPHOTOXIN-ALPHA; MALE; MICE; NF-KAPPA B; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION;

EID: 84868121821     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000341690     Document Type: Article

References (123)

1. Medzhitov R: Inflammation 2010: new adventures of an old flame. Cell 2010; 140: 771-776.
2. Pecchi E, Dallaporta M, Jean A, Thirion S, Troadec JD: Prostaglandins and sickness behavior: old story, new insights. Physiol Behav 2009; 97: 279-292.
3. Tracey KJ: The inflammatory reflex. Nature 2002; 420: 853-859.
4. Feghali CA, Wright TM: Cytokines in acute and chronic inflammation. Front Biosci 1997; 2:d12-d26.
5. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A: Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073-1081.
6. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
7. Grivennikov SI, Greten FR, Karin M: Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
8. Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M: Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta-and JNK1-dependent inflammation. Cancer Cell 2010; 17: 89-97.
9. Park EJ, Lee JH, Yu GY, et al: Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208.
10. Calle EE: Obesity and cancer. BMJ 2007; 335: 1107-1108.
11. Bollrath J, Greten FR: IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 2009; 10: 1314-1319.
12. Zong WX, Thompson CB: Necrotic death as a cell fate. Genes Dev 2006; 20: 1-15.
13. Rodier F, Coppe JP, Patil CK, et al: Persistent DNA damage signalling triggers senescenceassociated inflammatory cytokine secretion. Nat Cell Biol 2009; 11: 973-979.
14. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M: B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010; 464: 302-305.
15. Sayi A, Kohler E, Hitzler I, et al: The CD4+ T cell-mediated IFN-gamma response to Helicobacter infection is essential for clearance and determines gastric cancer risk. J Immunol 2009; 182: 7085-101.
16. Murdoch C, Muthana M, Coffelt SB, Lewis CE: The role of myeloid cells in the promotion of tumour angiogenesis. Nature Rev Cancer 2008; 8: 618-631.
17. Condeelis J, Pollard JW: Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124: 263-266.
18. Lin WW, Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117: 1175-1183.
19. Chung JY, Park YC, Ye H, Wu H: All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 2002; 115: 679-688.
20. Dempsey PW, Doyle SE, He JQ, Cheng G: The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003; 14: 193-209.
21. Chinnaiyan AM, Tepper CG, Seldin MF, et al: FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem 1996; 271: 4961-4965.
22. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A: Apo2L/ TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12: 611-620.
23. Micheau O, Tschopp J: Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 114: 181-190.
24. Hehlgans T, Pfeffer K: The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005; 115: 1-20.
25. Eck MJ, Sprang SR: The structure of tumor necrosis factor-alpha at 2.6 A resolution: implications for receptor binding. J Biol Chem 1989; 264: 17595-17605.
26. Loetscher H, Stueber D, Banner D, Mackay F, Lesslauer W: Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. J Biol Chem 1993; 268: 26350-26357.
27. Bossen C, Cachero TG, Tardivel A, et al: TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 2008; 111: 1004-1012.
28. Browning JL, Ngam-ek A, Lawton P, et al: Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 1993; 72: 847-856.
29. Browning JL, Dougas I, Ngam-ek A, et al: Characterization of surface lymphotoxin forms: use of specific monoclonal antibodies and soluble receptors. J Immunol 1995; 154: 33-46.
30. Young J, Yu X, Wolslegel K, et al: Lymphotoxin-alphabeta heterotrimers are cleaved by metalloproteinases and contribute to synovitis in rheumatoid arthritis. Cytokine 2010; 51: 78-86.
31. Ware CF: Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 2005; 23: 787-819.
32. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G: Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11: 700-714.
33. Remouchamps C, Boutaffala L, Ganeff C, Dejardin E: Biology and signal transduction pathways of the lymphotoxin-alphabeta/ LTbetaR system. Cytokine Growth Factor Rev 2011; 22: 301-310.
34. Ganeff C, Remouchamps C, Boutaffala L, et al: Induction of the alternative NF-kappaB pathway by lymphotoxin alphabeta (LTalphabeta) relies on internalization of LTbeta receptor. Mol Cell Biol 2011; 31: 4319-4334.
35. Coope HJ, Atkinson PG, Huhse B, et al: CD40 regulates the processing of NF-kappaB2 p100 to p52. EMBO J 2002; 21: 5375-5385.
36. Pomerantz JL, Baltimore D: Two pathways to NF-kappaB. Mol Cell 2002; 10: 693-695.
37. Dejardin E, Droin NM, Delhase M, et al: The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002; 17: 525-535.
38. Senftleben U, Cao Y, Xiao G, et al: Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001; 293: 1495-1499.
39. Ling L, Cao Z, Goeddel DV: NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. Proc Natl Acad Sci USA 1998; 95: 3792-3797.
40. Weih F, Caamano J: Regulation of secondary lymphoid organ development by the nuclear factor-kappaB signal transduction pathway. Immunol Rev 2003; 195: 91-105.
41. Zhu M, Fu YX: The role of core TNF/LIGHT family members in lymph node homeostasis and remodeling. Immunol Rev 2011; 244: 75-84.
42. Aggarwal BB: Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunology 2003; 3: 745-756.
43. Norris PS, Ware CF: The LT beta R signaling pathway: advances in experimental medicine and biology 2007; 597: 160-172.
44. De Togni P, Goellner J, Ruddle NH, et al: Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 1994; 264: 703-707.
45. Banks TA, Rouse BT, Kerley MK, et al: Lymphotoxin-alpha-deficient mice: effects on secondary lymphoid organ development and humoral immune responsiveness. J Immunol 1995; 155: 1685-1693.
46. Alimzhanov MB, Kuprash DV, Kosco-Vilbois MH, et al: Abnormal development of secondary lymphoid tissues in lymphotoxin beta-deficient mice. Proc Natl Acad Sci USA 1997; 94: 9302-9307.
47. Koni PA, Sacca R, Lawton P, Browning JL, Ruddle NH, Flavell RA: Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice. Immunity 1997; 6: 491-500.
48. Ngo VN, Korner H, Gunn MD, et al: Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J Exp Med 1999; 189: 403-412.
49. Futterer A, Mink K, Luz A, Kosco-Vilbois MH, Pfeffer K: The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 1998; 9: 59-70.
50. Rennert PD, Browning JL, Mebius R, Mackay F, Hochman PS: Surface lymphotoxin alpha/beta complex is required for the development of peripheral lymphoid organs. J Exp Med 1996; 184: 1999-2006.
51. Shinkura R, Kitada K, Matsuda F, et al: Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase. Nat Genet 1999; 22: 74-77.
52. Veiga-Fernandes H, Coles MC, Foster KE, et al: Tyrosine kinase receptor RET is a key regulator of Peyer's patch organogenesis. Nature 2007; 446: 547-551.
53. Adachi S, Yoshida H, Kataoka H, Nishikawa S: Three distinctive steps in Peyer's patch formation of murine embryo. Int Immunol 1997; 9: 507-514.
54. Hashi H, Yoshida H, Honda K, et al: Compartmentalization of Peyer's patch anlagen before lymphocyte entry. J Immunol 2001; 166: 3702-3709.
55. Honda K, Nakano H, Yoshida H, et al: Molecular basis for hematopoietic/mesenchymal interaction during initiation of Peyer's patch organogenesis. J Exp Med 2001; 193: 621-630.
56. Ansel KM, Ngo VN, Hyman PL, et al: A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000; 406: 309-314.
57. Ambrose CT: Immunology's first priority dispute-an account of the 17th-century Rudbeck-Bartholin feud. Cell Immunol 2006; 242: 1-8.
58. Kim D, Mebius RE, MacMicking JD, et al: Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J Exp Med 2000; 192: 1467-1478.
59. Rennert PD, James D, Mackay F, Browning JL, Hochman PS: Lymph node genesis is induced by signaling through the lymphotoxin beta receptor. Immunity 1998; 9: 71-79.
60. Hamada H, Hiroi T, Nishiyama Y, et al: Identification of multiple isolated lymphoid follicles on the antimesenteric wall of the mouse small intestine. J Immunol 2002; 168: 57-64.
61. Lorenz RG, Chaplin DD, McDonald KG, Mc-Donough JS, Newberry RD: Isolated lymphoid follicle formation is inducible and dependent upon lymphotoxin- sufficient B lymphocytes, lymphotoxin beta receptor, and TNF receptor I function. J Immunol 2003; 170: 5475-5482.
62. Bouskra D, Brezillon C, Berard M, et al: Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature 2008; 456: 507-510.
63. Eberl G, Littman DR: Thymic origin of intestinal alphabeta T cells revealed by fate mapping of RORgammat+ cells. Science 2004; 305: 248-251.
64. Spahn TW, Maaser C, Eckmann L, et al: The lymphotoxin-beta receptor is critical for control of murine Citrobacter rodentium-induced colitis. Gastroenterology 2004; 127: 1463-1473.
65. Lee YK, Mazmanian SK: Has the microbiota played a critical role in the evolution of the adaptive immune system? Science 2010; 330: 1768-1773.
66. Brandtzaeg P, Farstad IN, Johansen FE, Morton HC, Norderhaug IN, Yamanaka T: The B-cell system of human mucosae and exocrine glands. Immunol Rev 1999; 171: 45-87.
67. Fagarasan S: Intestinal IgA synthesis: a primitive form of adaptive immunity that regulates microbial communities in the gut. Curr Top Microbiol Immunol 2006; 308: 137-153.
68. Macpherson AJ, Smith K: Mesenteric lymph nodes at the center of immune anatomy. J Exp Med 2006; 203: 497-500.
69. McWilliams M, Phillips-Quagliata JM, Lamm ME: Mesenteric lymph node B lymphoblasts which home to the small intestine are precommitted to IgA synthesis. J Exp Med 1977; 145: 866-875.
70. Yamamoto M, Rennert P, McGhee JR, et al: Alternate mucosal immune system: organized Peyer's patches are not required for IgA responses in the gastrointestinal tract. J Immunol 2000; 164: 5184-5191.
71. Spahn TW, Fontana A, Faria AM, et al: Induction of oral tolerance to cellular immune responses in the absence of Peyer's patches. Eur J Immunol 2001; 31: 1278-1287.
72. Ryffel B, Le Hir M, Muller M, Eugster HP: Correction of the TNF-LT alpha-deficient phenotype by bone marrow transplantation. Dev Immunol 1998; 6: 253-260.
73. Kang HS, Chin RK, Wang Y, et al: Signaling via LTbetaR on the lamina propria stromal cells of the gut is required for IgA production. Nat Immunol 2002; 3: 576-582.
74. Agyekum S, Church A, Sohail M, et al: Expression of lymphotoxin-beta (LT-beta) in chronic inflammatory conditions. J Pathol 2003; 199: 115-121.
75. Jungbeck M, Daller B, Federhofer J, et al: Neutralization of LIGHT ameliorates acute dextran sodium sulphate-induced intestinal inflammation. Immunology 2009; 128: 451-458.
76. Zheng Y, Valdez PA, Danilenko DM, et al: Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008; 14: 282-289.
77. Tumanov AV, Koroleva EP, Guo X, et al: Lymphotoxin controls the IL-22 protection pathway in gut innate lymphoid cells during mucosal pathogen challenge. Cell Host Microbe 2011; 10: 44-53.
78. Barthel M, Hapfelmeier S, Quintanilla-Martinez L, et al: Pretreatment of mice with streptomycin provides a Salmonella enterica serovar Typhimurium colitis model that allows analysis of both pathogen and host. Infect Immun 2003; 71: 2839-2858.
79. Messer G, Spengler U, Jung MC, et al: Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 1991; 173: 209-219.
80. Chae YS, Kim JG, Sohn SK, et al: Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP. Cancer Chemother Pharmacol 2010; 65: 571-577.
81. Nonomura N, Tokizane T, Nakayama M, et al: Possible correlation between polymorphism in the tumor necrosis factor-beta gene and the clinicopathological features of bladder cancer in Japanese patients. Int J Urol 2006; 13: 971-976.
82. Niwa Y, Ito H, Matsuo K, et al: Lymphotoxinalpha polymorphisms and the risk of endometrial cancer in Japanese subjects. Gynecol Oncol 2007; 104: 586-590.
83. Takei K, Ikeda S, Arai T, Tanaka N, Muramatsu M, Sawabe M: Lymphotoxin-alpha polymorphisms and presence of cancer in 1,536 consecutive autopsy cases. BMC Cancer 2008; 8: 235.
84. Or YY, Chung GT, To KF, et al: Identification of a novel 12p13.3 amplicon in nasopharyngeal carcinoma. J Pathol 2010; 220: 97-107.
85. Compagno M, Lim WK, Grunn A, et al: Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009; 459: 717-721.
86. Keats JJ, Fonseca R, Chesi M, et al: Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12: 131-144.
87. Yamagishi M, Nakano K, Miyake A, et al: Polycomb-mediated loss of miR-31 activates NIK-dependent NF-kappaB pathway in adult T cell leukemia and other cancers. Cancer Cell 2012; 21: 121-135.
88. Fujiwara S, Yamashita Y, Choi YL, et al: Transforming activity of the lymphotoxinbeta receptor revealed by expression screening. Biochem Biophys Res Commun 2005; 338: 1256-1262.
89. Luo JL, Tan W, Ricono JM, et al: Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 2007; 446: 690-694.
90. Tan W, Zhang W, Strasner A, et al: Tumourinfiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011; 470: 548-553.
91. Browning JL, Miatkowski K, Sizing I, et al: Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines. J Exp Med 1996; 183: 867-878.
92. Lukashev M, LePage D, Wilson C, et al: Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy. Cancer Res 2006; 66: 9617-9624.
93. Rayet B, Gelinas C: Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999; 18: 6938-6947.
94. Wang Y, Cui H, Schroering A, et al: NFkappa B2 p100 is a pro-apoptotic protein with anti-oncogenic function. Nat Cell Biol 2002; 4: 888-893.
95. Ito D, Back TC, Shakhov AN, Wiltrout RH, Nedospasov SA: Mice with a targeted mutation in lymphotoxin-alpha exhibit enhanced tumor growth and metastasis: impaired NK cell development and recruitment. J Immunol 1999; 163: 2809-2815.
96. Zhou P, Fang X, McNally BA, et al: Targeting lymphotoxin-mediated negative selection to prevent prostate cancer in mice with genetic predisposition. Proc Natl Acad Sci USA 2009; 106: 17134-17139.
97. Kim DH, Kim EM, Lee EH, et al: Human papillomavirus 16E6 suppresses major histocompatibility complex class I by upregulating lymphotoxin expression in human cervical cancer cells. Biochem Biophys Res Commun 2011; 409: 792-798.
98. Rehm A, Mensen A, Schradi K, et al: Cooperative function of CCR7 and lymphotoxin in the formation of a lymphoma-permissive niche within murine secondary lymphoid organs. Blood 2011; 118: 1020-1033.
99. Hehlgans T, Stoelcker B, Stopfer P, et al: Lymphotoxin-beta receptor immune interaction promotes tumor growth by inducing angiogenesis. Cancer Res 2002; 62: 4034-4040.
100. Daller B, Musch W, Rohrl J, et al: Lymphotoxin-beta receptor activation by lymphotoxin-alpha(1)beta(2) and LIGHT promotes tumor growth in an NFkappaB-dependent manner. Int J Cancer 2011; 128: 1363-1370.
101. Kuprash DV, Qin Z, Ito D, et al: Ablation of TNF or lymphotoxin signaling and the frequency of spontaneous tumors in p53-deficient mice. Cancer Lett 2008; 268: 70-75.
102. Anders RA, Subudhi SK, Wang J, Pfeffer K, Fu YX: Contribution of the lymphotoxin beta receptor to liver regeneration. J Immunol 2005; 175: 1295-1300.
103. Tumanov AV, Koroleva EP, Christiansen PA, et al: T cell-derived lymphotoxin regulates liver regeneration. Gastroenterology 2009; 136: 694-704 e4.
104. Ruddell RG, Knight B, Tirnitz-Parker JE, et al: Lymphotoxin-beta receptor signaling regulates hepatic stellate cell function and wound healing in a murine model of chronic liver injury. Hepatology 2009; 49: 227-239.
105. Lo JC, Wang Y, Tumanov AV, et al: Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science 2007; 316: 285-288.
106. Anand S, Wang P, Yoshimura K, et al: Essential role of TNF family molecule LIGHT as a cytokine in the pathogenesis of hepatitis. J Clin Invest 2006; 116: 1045-1051.
107. An MM, Fan KX, Cao YB, et al: Lymphtoxin beta receptor-Ig protects from T-cell-mediated liver injury in mice through blocking LIGHT/HVEM signaling. Biol Pharm Bull 2006; 29: 2025-2030.
108. Chen CM, You LR, Hwang LH, Lee YH: Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin-beta receptor modulates the signal pathway of the lymphotoxin-beta receptor. J Virol 1997; 71: 9417-9426.
109. Matsumoto M, Hsieh TY, Zhu N, et al: Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor. J Virol 1997; 71: 1301-1309.
110. Lowes KN, Croager EJ, Abraham LJ, Olynyk JK, Yeoh GC: Upregulation of lymphotoxin beta expression in liver progenitor (oval) cells in chronic hepatitis C. Gut 2003; 52: 1327-1332.
111. Ng TI, Mo H, Pilot-Matias T, et al: Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology. Hepatology 2007; 45: 1413-1421.
112. Lee SH, Park SG, Lim SO, Jung G: The hepatitis B virus X protein up-regulates lymphotoxin alpha expression in hepatocytes. Biochim Biophys Acta 2005; 1741: 75-84.
113. Washburn ML, Kovalev GI, Koroleva E, Fu YX, Su L: LIGHT induces distinct signals to clear an AAV-expressed persistent antigen in the mouse liver and to induce liver inflammation. PLoS One;5:e10585.
114. Haybaeck J, Zeller N, Wolf MJ, et al: A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009; 16: 295-308.
115. Wang Y, Koroleva EP, Kruglov AA, et al: Lymphotoxin beta receptor signaling in intestinal epithelial cells orchestrates innate immune responses against mucosal bacterial infection. Immunity 2010; 32: 403-413.
116. Ehlers S, Holscher C, Scheu S, et al: The lymphotoxin beta receptor is critically involved in controlling infections with the intracellular pathogens Mycobacterium tuberculosis and Listeria monocytogenes. J Immunol 2003; 170: 5210-5218.
117. Xu G, Liu D, Fan Y, et al: Lymphotoxin alpha beta 2 (membrane lymphotoxin) is critically important for resistance to Leishmania major infection in mice. J Immunol 2007; 179: 5358-5366.
118. Engwerda CR, Ato M, Stager S, Alexander CE, Stanley AC, Kaye PM: Distinct roles for lymphotoxin-alpha and tumor necrosis factor in the control of Leishmania donovani infection. Am J Pathol 2004; 165: 2123-2133.
119. Chiang EY, Kolumam GA, Yu X, et al: Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 2009; 15: 766-773.
120. Levisetti MG, Suri A, Frederick K, Unanue ER: Absence of lymph nodes in NOD mice treated with lymphotoxin-beta receptor immunoglobulin protects from diabetes. Diabetes 2004; 53: 3115-3119.
121. Dharmana E, Keuter M, Netea MG, Verschueren IC, Kullberg BJ: Divergent effects of tumor necrosis factor-alpha and lymphotoxin-alpha on lethal endotoxemia and infection with live Salmonella typhimurium in mice. Eur Cytokine Netw 2002; 13: 104-109.
122. Jungbeck M, Stopfer P, Bataille F, Nedospasov SA, Mannel DN, Hehlgans T: Blocking lymphotoxin beta receptor signalling exacerbates acute DSS-induced intestinal inflammation-opposite functions for surface lymphotoxin expressed by T and B lymphocytes. Mol Immunol 2008; 45: 34-41.
123. Engwerda CR, Mynott TL, Sawhney S, De Souza JB, Bickle QD, Kaye PM: Locally upregulated lymphotoxin alpha, not systemic tumor necrosis factor alpha, is the principle mediator of murine cerebral malaria. J Exp Med 2002; 195: 1371-1377.